Current Advances in the Translation of Vascular Tissue Engineering to the Treatment of Pediatric Congenital Heart Disease

Yale Journal of Biology and Medicine

Volumn 85, Issue 2, 2012, Pages 229-238

  Dean, Ethan W ^a   Udelsman, Brooks ^a   Breuer, Christopher K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow derived mononuclear cells; Congenital heart disease; Extracellular matrix; Tissue engineering; Tissue engineered vascular grafts; Translational research; Vascular remodeling

Indexed keywords

INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE SCAFFOLD; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BLOOD VESSEL GRAFT; CARDIAC IMAGING; CAVOPULMONARY CONNECTION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONGENITAL HEART DISEASE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FONTAN PROCEDURE; GRAFT FAILURE; GRAFT OCCLUSION; HISTOGENESIS; HUMAN; NEWBORN DEATH; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; REVIEW; SMOOTH MUSCLE FIBER; TISSUE ENGINEERING; TISSUE REGENERATION; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL TYPE; CELL VIABILITY; CULTURE TECHNIQUE; FOLLOW UP; PILOT STUDY; STENOSIS; SURGICAL RISK;

ANIMALS; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CHILD; HEART DEFECTS, CONGENITAL; HUMANS; MODELS, ANIMAL; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA;

EID: 84863473407     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3(1):104-14.
2. Sapsford RN, Oakley GD, Talbot S. Early and late patency of expanded polytetrafluoroethylene vascular grafts in aorta-coronary bypass. J Thorac Cardiovasc Surg. 1981;81(6):860-4.
3. Klinkert P, Post PN, Breslau PJ, Van bockel JH. Saphenous vein versus PTFE for aboveknee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004;27(4):357-62.
4. Langer R, Vacanti JP. Tissue engineering. Science. 1993;260(5110):920-6.
5. Shinoka T, Shum-tim D, Ma PX, Tanel RE, Isogai N, Langer R, et al. Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg. 1998;115(3):536-45.
6. Matsumura G, Hibino N, Ikada Y, Kurosawa H, Shin'oka T. Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials. 2003;24(13):2303-8.
7. Matsumura G, Ishihara Y, Miyagawa-tomita S, Ikada Y, Matsuda S, Kurosawa H, et al. Evaluation of tissue-engineered vascular autografts. Tissue Eng. 2006;12(11):3075-83.
8. Watanabe M, Shin'oka T, Tohyama S, Hibino N, Konuma T, Matsumura G, et al. Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng. 2001;7(4):429-39.
9. American Heart Association. 2008 Annual Report.
10. Van der linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and metaanalysis. J Am Coll Cardiol. 2011;58(21):2241-7.
11. Samánek M. Children with congenital heart disease: probability of natural survival. Pediatr Cardiol. 1992;13(3):152-8.
12. Giannico S, Hammad F, Amodeo A, Michielon G, Drago F, Turchetta A, et al. Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006;47(10):2065-73.
13. Petrossian E, Reddy VM, Collins KK, Culbertson CB, MacDonald MJ, Lamberti JJ, et al. The extracardiac conduit Fontan operation using minimal approach extracorporeal circulation: early and midterm outcomes. J Thorac Cardiovasc Surg. 2006;132(5):1054-63.
14. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12):1890-900.
15. Conte MS. The ideal small arterial substitute: a search for the Holy Grail? FASEB J. 1998;12(1):43-5.
16. Kakisis JD, Liapis CD, Breuer C, Sumpio BE. Artificial blood vessel: the Holy Grail of peripheral vascular surgery. J Vasc Surg. 2005;41(2):349-54.
17. Dearani JA, Danielson GK, Puga FJ, Schaff HV, Warnes CW, Driscoll DJ, et al. Late follow-up of 1095 patients undergoing operation for complex congenital heart disease utilizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac Surg. 2003;75(2):399-410.
18. Alexi-meskishvili V, Ovroutski S, Ewert P, Dähnert I, Berger F, Lange PE, et al. Optimal conduit size for extracardiac Fontan operation. Eur J Cardiothorac Surg. 2000;18(6):690-5.
19. Van son JA, Reddy M, Hanley FL. Extracardiac modification of the Fontan operation without use of prosthetic material. J Thorac Cardiovasc Surg. 1995;110(6):1766-8.
20. Bermudez CA, Dearani JA, Puga FJ, Schaff HV, Warnes CA, O'Leary PW, et al. Late results of the peel operation for replacement of failing extracardiac conduits. Ann Thorac Surg. 2004;77(3):881-7.
21. Jonas RA, Freed MD, Mayer JE, Castaneda AR. Long-term follow-up of patients with synthetic right heart conduits. Circulation. 1985;72(3 Pt 2):1177-83.
22. Homann M, Haehnel JC, Mendler N, Paek SU, Holper K, Meisner H, et al. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. Eur J Cardiothorac Surg. 2000;17(6):624-30.
23. Shin'oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med. 2001;344(7):532-3.
24. Naito Y, Imai Y, Shin'oka T, Kashiwagi J, Aoki M, Watanabe M, et al. Successful clinical application of tissue-engineered graft for extracardiac Fontan operation. J Thorac Cardiovasc Surg. 2003;125(2):419-20.
25. Hibino N, Mcgillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, et al. Late-term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg. 2010;139(2):431-6, 436. e1-2.
26. Gui L, Zhao L, Spencer RW, Burghouwt A, Taylor MS, Shalaby SW, et al. Development of novel biodegradable polymer scaffolds for vascular tissue engineering. Tissue Eng Part A. 2011;17(9-10):1191-200.
27. Naito Y, Shinoka T, Duncan D, Hibino N, Solomon D, Cleary M, et al. Vascular tissue engineering: towards the next generation vascular grafts. Adv Drug Deliv Rev. 2011;63(4-5):312-23.
28. Duncan DR, Breuer CK. Challenges in translating vascular tissue engineering to the pediatric clinic. Vasc Cell. 2011;3(1):23.
29. He W, Yong T, Teo WE, Ma Z, Ramakrishna S. Fabrication and endothelialization of collagen-blended biodegradable polymer nanofibers: potential vascular graft for blood vessel tissue engineering. Tissue Eng. 2005;11(9-10):1574-88.
30. Quint C, Kondo Y, Manson RJ, Lawson JH, Dardik A, Niklason LE. Decellularized tissue-engineered blood vessel as an arterial conduit. Proc Natl Acad Sci USA. 2011;108(22):9214-9.
31. Hoenicka M, Lehle K, Jacobs VR, Schmid FX, Birnbaum DE. Properties of the human umbilical vein as a living scaffold for a tissue-engineered vessel graft. Tissue Eng. 2007;13(1):219-29.
32. Dahl SL, Kypson AP, Lawson JH, Blum JL, Strader JT, Li Y, et al. Readily available tissue-engineered vascular grafts. Sci Transl Med. 2011;3(68):68ra9.
33. Weber B, Emmert MY, Schoenauer R, Brokopp C, Baumgartner L, Hoerstrup SP. Tissue engineering on matrix: future of autologous tissue replacement. Semin Immunopathol. 2011;33(3):307-15.
34. Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev. 2005;19(6):321-31.
35. Hibino N, Duncan DR, Nalbandian A, Yi T, Qyang Y, Shinoka T, et al. Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts. J Thorac Cardiovasc Surg. Forthcoming 2012.
36. Hibino N, Nalbandian A, Devine L, Martinez RS, McGillicuddy E, Yi T, et al. Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: novel filter system versus traditional density centrifugation method. Tissue Eng Part C Methods. 2011;17(10):993-8.
37. Villalona GA, Udelsman B, Duncan DR, McGillicuddy E, Sawh-Martinez RF, Hibino N, et al. Cell-seeding techniques in vascular tissue engineering. Tissue Eng Part B Rev. 2010;16(3):341-50.
38. Udelsman B, Hibino N, Villalona GA, McGillicuddy E, Nieponice A, Sakamoto Y, et al. Development of an operator-independent method for seeding tissue-engineered vascular grafts. Tissue Eng Part C Methods. 2011;17(7):731-6.
39. Brennan MP, Dardik A, Hibino N, Roh JD, Nelson GN, Papademitris X, et al. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann Surg. 2008;248(3):370-7.
40. Roh JD, Nelson GN, Brennan MP, Mirensky TL, Yi T, Hazlett TF, et al. Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials. 2008;29(10):1454-63.
41. Roh JD, Sawh-martinez R, Brennan MP, Jay SM, Devine L, Rao DA, et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci USA. 2010;107(10):4669-74.
42. Matsumura G, Miyagawa-tomita S, Shin'oka T, Ikada Y, Kurosawa H. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation. 2003;108(14):1729-34.
43. Hibino N, Yi T, Duncan DR, Dean E, Naito Y, Dardik A, et al. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 2011;25(12):4253-63.
44. Bergmann CE, Hoefer IE, Meder B, Roth H, van Royen N, Breit SM, et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol. 2006;80(1):59-65.
45. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998;101(1):40-50.
46. Danenberg HD, Fishbein I, Gao J, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002;106(5):599-605.
47. Hibino N, Villalona G, Pietris N, Duncan DR, Schoffner A, Roh JD, et al. Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J. 2011;25(8):2731-9.
48. Harrington JK, Chahboune H, Criscione JM, Li AY, Hibino N, Yi T, et al. Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI. FASEB J. 2011;25(12):4150-61.
49. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3):221-33.
50. Naito Y, Williams-fritze M, Duncan DR, Church SN, Hibino N, Madri JA, et al. Characterization of the natural history of extracellular matrix production in tissue-engineered vascular grafts during neovessel formation. Cells Tissues Organs (Print). 2012;195(1-2):60-72.
51. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75(3):539-45.
52. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation. 2000;102(23):2861-6.
53. Shinoka T, Breuer C. Tissue-engineered blood vessels in pediatric cardiac surgery. Yale J Biol Med. 2008;81(4):161-6.
54. Breuer CK. The development and translation of the tissue-engineered vascular graft. J Pediatr Surg. 2011;46(1):8-17.